ArticleAnnals of clinical and translational neurology2025
Medication Use in Multiple Sclerosis: A Population-Based Comparison With the General Danish Population.
Article in Annals of clinical and translational neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Gastrointestinal symptoms and disorders in multiple sclerosis: a systematic review and meta-analysis.Journal of neurology · 2026Pooled it
- Trigger zones in trigeminal neuralgia: clinical features, pathophysiological mechanisms, and therapeutic strategies.Frontiers in neurology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo investigate the overall use of prescription medications among individuals with multiple sclerosis compared to the general population, with a focus on treatments beyond disease-modifying therapies.
methodsWe conducted a nationwide, registry-based study in Denmark. All residents with a diagnosis of multiple sclerosis aged 20-80 years and alive on January 1, 2023, were included and followed for 1 year. Each patient was matched with 10 individuals from the general population based on age, sex, and residence. Prescription data were obtained from the Danish National Prescription Registry and categorized using the Anatomical Therapeutic Chemical classification. Relative risks of medication use were calculated.
resultsA total of 14,491 individuals with multiple sclerosis and 144,910 matched controls were included. Patients with multiple sclerosis had significantly higher use of several therapeutic drug classes, including analgesics (51% vs. 33%; RR: 1.56, 95% CI: 1.52-1.60), agents for constipation (12% vs. 3%; RR: 4.61, 95% CI: 4.36-4.88), spasmolytics, and urological medications. Among specific drugs, the most pronounced differences were observed for modafinil (RR: 323.33, 95% CI: 228.67-457.19), baclofen (RR: 36.51, 95% CI: 33.33-39.99), and fesoterodine (RR: 36.36, 95% CI: 18.66-70.87). In contrast, individuals with multiple sclerosis had lower usage of antidiabetic medications and treatments for chronic obstructive pulmonary disease.
interpretationThis large, population-based study reveals extensive use of medications targeting symptoms and comorbidities in individuals with multiple sclerosis. These insights can guide healthcare providers in optimizing patient management, addressing overlooked treatment needs, and improving overall care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.